Fibronectin Fragments for Growth Factor Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for wounds and cancer lack effective methods to deliver and retain the biological activity of growth factors, such as TGF-β1, PDGF-BB, VEGF-A, and FGF-2, which are essential for tissue repair and proliferation.
Innovation Solution
Fibronectin fragments, specifically derived from human plasma or ECM fibronectin, are used to bind and deliver growth factors, maintaining or enhancing their biological activity, thereby facilitating wound healing and cancer treatment by promoting tissue repair and cell migration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If growth factors are administered alone, then they can perform their biological function, but they lack effective delivery and retention mechanisms at the target site
Solution Approach 1:
The patent uses fibronectin fragments as intermediary molecules that bind to growth factors and facilitate their delivery to target sites. The fibronectin fragment acts as a mediator between the growth factor and the target tissue, providing both delivery and retention functions while maintaining the simplicity of the overall system.
2Reliability
If fibronectin fragments are used to bind growth factors, then delivery and retention are improved, but the molecular weight and size of the complex increase
Solution Approach 1:
The patent extracts only the essential binding domain of fibronectin (a fragment rather than the full-length protein) to create a smaller, more efficient delivery vehicle. This extraction principle allows the system to retain the growth factor-binding and delivery functions while significantly reducing the molecular weight compared to using full-length fibronectin.
3Quantity of substance
If full-length fibronectin is used, then growth factor binding capacity is sufficient, but the size and complexity of the molecule increases
Solution Approach 1:
The patent segments the full-length fibronectin molecule into smaller functional fragments that retain the essential growth factor-binding capability. This segmentation reduces molecular complexity and size while maintaining sufficient binding capacity, as the critical binding domains are preserved in the fragmented structure.
4Reliability
If growth factors are delivered without a carrier, then the system remains simple, but the biological activity is not retained or enhanced at the target site
Solution Approach 1:
The fibronectin fragment serves as an intermediary carrier that not only delivers the growth factor but also enhances and retains its biological activity at the target site. This intermediary approach ensures reliable biological activity retention while adding minimal complexity to the system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of fibronectin fragments effectively binds and delivers growth factors, enhancing their activity and promoting tissue repair, accelerating wound healing and potentially inhibiting cancer growth by maintaining or increasing their biological efficacy in therapeutic applications.
Implementation Method 1
fragments of fibronectin (FN), including fragments within domains FNIII1-2, H and HV, promiscuously bind growth factors
Data Source
AI summary
Described herein are fragments of fibronectin and variants thereof that bind growth factors. Compositions containing such a fragment of fibronectin are therefore useful in sequestering growth factors, and complexes containing both a FN fragment and a bound, active growth factor can be used to deliver growth factors to a patient (e.g., to a wound on the patient's skin).